Donor-derived CD34+ HSC with CRISPR/Cas9-mediated CD33 deletion(German Cancer Research Center)

N/A

Report date: 2023/01/12 15:52:38

Base Information

Drug NameDonor-derived CD34+ HSC with CRISPR/Cas9-mediated CD33 deletion(German Cancer Research Center)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapy
Mechanisms of ActionHematopoietic progenitor cell antigen CD34 modulators
TargetsHematopoietic progenitor cell antigen CD34
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermany
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesGerman Cancer Research Center (Dkfz)
China Registration ClassN/A

Develop Information

Active CompaniesGerman Cancer Research Center (Dkfz)
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A